Drug intelligence / Profile preview

isoxicam

Development stage: Discontinued
Lead developer: Pfizer
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Isoxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. It acts as a nonselective inhibitor of cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of prostaglandins involved in pain and inflammation. Isoxicam was developed for the treatment of rheumatoid arthritis and degenerative joint disease (osteoarthritis), with clinical studies indicating efficacy in reducing pain and inflammation associated with these conditions. It is an orally active agent with a long duration of action[6][7][10].

Brand names: MaxicamPacyl
Other names: IsoxicamumIsoxicamo4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on isoxicam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoxicam.

Explore the full profile